Status:
COMPLETED
A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice
Lead Sponsor:
Bayer
Conditions:
Solid Tumors Harboring NTRK Fusion
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational study in which patient data from the past of adult people with solid tumors harboring NTRK gene fusion are studied. This study will focus on 5 tumor types which have been at t...
Eligibility Criteria
Inclusion
- Diagnosis of advanced stage of disease or metastatic disease.
Exclusion
- Patients involved in TRK inhibitor clinical trials will be excluded from RW control cohort.
Key Trial Info
Start Date :
December 3 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2023
Estimated Enrollment :
368 Patients enrolled
Trial Details
Trial ID
NCT05192642
Start Date
December 3 2021
End Date
August 31 2023
Last Update
November 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bayer
Whippany, New Jersey, United States, 07981